Amarin Corp. PLC (NASDAQ:AMRN)’s share price traded up 2.7% on Tuesday . The company traded as high as $2.69 and last traded at $2.64, with a volume of 1,474,693 shares trading hands. The stock had previously closed at $2.57.

A number of equities analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Amarin Corp. PLC in a research report on Monday, August 8th. Zacks Investment Research upgraded Amarin Corp. PLC from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research report on Thursday, August 4th. Finally, Jefferies Group reiterated a “buy” rating on shares of Amarin Corp. PLC in a research report on Wednesday, June 8th.

The company has a 50 day moving average price of $3.04 and a 200 day moving average price of $2.18. The firm’s market capitalization is $489.06 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/amarin-corp-plc-amrn-trading-2-7-higher.html

Amarin Corp. PLC (NASDAQ:AMRN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. The company had revenue of $32.82 million for the quarter, compared to analyst estimates of $29.97 million. During the same period last year, the company posted ($0.15) earnings per share. The business’s revenue for the quarter was up 85.4% on a year-over-year basis. Equities research analysts predict that Amarin Corp. PLC will post ($0.46) earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Fund Advisors boosted its position in shares of Amarin Corp. PLC by 11.0% in the first quarter. BlackRock Fund Advisors now owns 2,293,101 shares of the biopharmaceutical company’s stock valued at $3,508,000 after buying an additional 228,088 shares during the period. UBS Group AG raised its stake in Amarin Corp. PLC by 6.5% in the first quarter. UBS Group AG now owns 551,920 shares of the biopharmaceutical company’s stock valued at $845,000 after buying an additional 33,662 shares in the last quarter. A.R.T. Advisors LLC raised its stake in Amarin Corp. PLC by 107.8% in the first quarter. A.R.T. Advisors LLC now owns 133,962 shares of the biopharmaceutical company’s stock valued at $204,000 after buying an additional 69,500 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Amarin Corp. PLC during the second quarter valued at about $210,000. Finally, Timber Hill LLC raised its stake in Amarin Corp. PLC by 229.8% in the second quarter. Timber Hill LLC now owns 53,504 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 37,283 shares in the last quarter. 20.74% of the stock is owned by hedge funds and other institutional investors.

Amarin Corp. PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

5 Day Chart for NASDAQ:AMRN

Receive News & Ratings for Amarin Corp. PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corp. PLC and related companies with MarketBeat.com's FREE daily email newsletter.